EC approves Novo's combo for Type II

The European Commission approved Xultophy ( IDegLira) from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) to improve glycemic control in adults with Type II diabetes. The approval is for use in combination with oral glucose-lowering products for patients inadequately controlled by those alone or combined with basal insulin.

Novo expects to launch Xultophy in the EU in 1H15. The once-daily fixed-dose combination of the company's Victoza liraglutide and Tresiba insulin degludec was approved in Switzerland on Sept. 12. ...